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Introduction: Polymorphonuclear leukocytes (PMN) are main effector cells in the acute immune response. While
the specific role of PMN in systemic lupus erythematosus (SLE) and autoimmunity is still unclear, their importance
in chronic inflammation is gaining more attention. Here we investigate aspects of function, bone marrow release
and activation of PMN in patients with SLE.
Methods: The following PMN functions and subsets were evaluated using flow cytometry; (a) production of
reactive oxygen species (ROS) after ex vivo stimulation with phorbol 12-myristate 13-acetate (PMA) or Escherichia coli
(E. coli); (b) capacity to phagocytose antibody-coated necrotic cell material; (c) PMN recently released from bone
marrow, defined as percentage of CD10−D16low in peripheral blood, and (d) PMN activation markers; CD11b, CD62L
and C5aR.
Results: SLE patients (n = 92) showed lower ROS production compared with healthy controls (n = 38) after
activation ex vivo. The ROS production was not associated with corticosteroid dose or other immunotherapies. PMA
induced ROS production was significantly reduced in patients with severe disease. In contrast, neither ROS levels
after E. coli activation, nor the capacity to phagocytose were associated with disease severity. This suggests that
decreased ROS production after PMA activation is a sign of changed PMN behaviour rather than generally impaired
functions. The CD10−CD16low phenotype constitute 2% of PMN in peripheral blood of SLE patients compared with
6.4% in controls, indicating a decreased release of PMN from the bone marrow in SLE. A decreased expression of
C5aR on PMN was observed in SLE patients, pointing towards in vivo activation.
Conclusions: Our results indicate that PMN from SLE patients have altered function, are partly activated and are
released abnormally from bone marrow. The association between low ROS formation in PMN and disease severity is
consistent with findings in other autoimmune diseases and might be considered as a risk factor.Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease affecting several organ systems such
as skin, joints, kidneys and central nervous system. Many
of the disease manifestations in SLE are related to immune
complexes, consisting of autoantibodies and remnants of
apoptotic cells [1]. Apoptotic cells are thought to be a* Correspondence: asa.johansson@med.lu.se
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article, unless otherwise stated.major source of auto-antigens in SLE, partly because of
impaired clearance [2,3]. Another potential antigen source
is the neutrophil extracellular traps (NETs) that consist of
chromatin and antimicrobial enzymes released from neu-
trophils to trap and kill pathogens. Serum from some SLE
patients have a reduced ability to degrade NETs [4,5].
Polymorphonuclear leukocytes (PMN), such as neu-
trophils, are produced in the bone marrow and released
to circulation. During acute inflammation an increased
mobilization of neutrophils from the bone marrow oc-
curs, which can be observed as increased percentage of
CD10−CD16low neutrophils in peripheral blood [6,7]. The
role of PMN in chronic inflammation and autoimmunitytral Ltd. This is an Open Access article distributed under the terms of the
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to be the primary mediators of end organ-damage res-
ponding to deposited immune complexes [8,9]. PMN are
recruited to inflammatory sites, and activated by pro-
inflammatory mediators like complement factors, cytokines
and chemokines. Upon activation the expression of various
surface proteins changes; for example, C5aR and CD62L
are down regulated whereas an increase in CD11b expres-
sion is observed [10,11]. In addition to the changing expres-
sion of surface proteins, activated PMN are primed to
release granules and produce reactive oxygen species (ROS)
by the nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH) complex [12]. ROS are major effector
molecules in inflammatory processes and tightly linked to
NETs formation. During the last decade, an increasing
amount of data support a T-cell regulating role for mono-
cyte and PMN-produced ROS [13–16]. Furthermore, the
association of SLE to polymorphism in NCF2, encoding a
protein in the NADPH oxidase complex, adds support for
the importance of ROS in this disease [17]. Of note,Table 1 Patients characteristics and demographics
All
(n
Age, median (range) years 48 (2
Female gender, n (%) 81
Disease duration, median (range) years 14 (
SLEDAI, median (range) 2 (0
SLICC/ACR-DI median (range) 1 (
PMN 109/L median (range) 4.0 (<
Disease manifestations at time of sampling, n
Lupus headache
Arthritis
Kidney involvement (urinary cast, hematuria, proteinuria, or pyuria)
Rash
Alopecia
Low complement (C3 or C4)
Anti-double stranded DNA antibodies
Leukopenia
Treatment
Prednisone, % (median dose of treated patients) 53
Hydroxychloroquine, % (n) 5
Chloroquine phosphate, % (n)
Azathioprine, % (n) 2
Mycophenolate mofetil%, (n) 1
Rituximab, % (n)
Methotrexates, % (n)
Cyclosporine A, % (n)
SLICC/ACR-DI, Systemic Lupus International Collaborative Clinics/American College of R
disease activity index 2000; PMN, polymorphonuclear leukocytes.patients with chronic granulomatous disease, lacking a
functional NADPH oxidase complex, show autoimmune
features such as high levels of immunoglobulins and auto-
antibodies, as well as an increased risk of Crohn’s disease
and discoid lupus [18,19].
This study aims at characterizing PMN from SLE pa-
tients (SLE-PMN), in regard to function, bone marrow
release and activation to gain knowledge of the role of
PMN in SLE and autoimmunity.
Methods
Patients and controls
SLE patients (n = 107) were recruited to the study, when
coming to their scheduled visit at the Department of
Rheumatology, Skåne University Hospital, Lund, Sweden.
All patients fulfilled at least four American College of
Rheumatology classification criteria for SLE [20]. Disease
activity was assessed using the systemic lupus erythemato-
sus disease activity index 2000 (SLEDAI-2 K) [21], and
organ damage was evaluated according to the Systemicpatients
= 92)
No organ damage
SLICC/ACR-DI = 0 (n = 42)
Organ damage
SLICC/ACR-DI ≥1 (n = 50)
2 to 84) 43 (22 to 79) 60 (24 to 84)
(88%) 37 (88%) 44 (88%)
0 to 51) 9 (0 to 29) 19 (0 to 51)
to 16) 2 (0 to 16) 1 (0 to 13)
0 to 8) 0 2 (1 to 8)









(5 mg) 60 (5 mg) 50 (6.25 mg)
9 (54) 69 (29) 50 (25)
2 (2) 2 (1) 2 (1)
4 (22) 29 (12) 20 (10)
2 (11) 14 (6) 10 (5)
2 (2) 0 (0) 4 (2)
4 (4) 5 (2) 4 (2)
2 (2) 0 (0) 4 (2)
heumatology (ACR) damage index; SLEDAI-2 K, Systemic lupus erythematosus
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lege of Rheumatology damage index (SLICC/ACR-DI) [22].
Demographic and clinical characteristics are shown in
Table 1. Healthy blood donors (n = 38, Blood centre in
Lund) and healthy volunteers (n = 15) were recruited as
controls; ages 18 to 65 years. Complement proteins and
autoantibodies were measured using routine analyses
(Clinical Immunology and Transfusion Medicine, University
and Regional laboratories, Region Skåne, Lund Sweden).
The study was approved by the Regional Ethics Review
Board at Lund University (file number LU 2010-708) and
informed consent was obtained from all participants.
Oxidative burst and expression of surface markers
ROS production in peripheral blood PMN was investigated
using the PhagoBurst assay, Glycotope Biotechnology,
GmBH, Germany, according to the manufacturer’s proto-
col after activation with phorbol 12-myristate 13-acetate
(PMA) or opsonised Escherichia coli (E. coli), and analysed
using flow cytometry. At least 15,000 PMN were analysed
based on forward and side scatter properties. No patient
with ROS deficiency was observed.
ROS formation in peripheral blood PMN was also quan-
tified by oxidation of 2,7-dichlorofluorescein-diacetate
(DCFH-DA, Sigma-Aldrich®, St. Louis, MO, USA), as previ-
ously described [23]. As stimuli PMA and E. coli from the
PhagoBurst kit or Staphylococcus aureus (ATCC 25923, 1
leukocyte: 2,000 bacterial cells) and Pseudomonas aerugi-
nosa (ATCC 27853, 1 leukocyte: 200 bacterial cells) were
used. S. aureus and P. aeruginosa were grown in liquid
Tryptic Soy Broth (TSB) medium overnight at 37°C and
killed by heat (60°C) for 2 h. To confirm bacterial inactiva-
tion a sample was inoculated in TSB and kept for 48 h.
The bacteria were centrifuged and re-suspended in 0.8%
saline. Optical density was adjusted to 24 × 108 colony form-
ing units/mL by comparing turbidity to a McFarland scale
number 8 BaSO4 standard solution. DCFH-DA was added
to heparinised whole blood before the various stimuli, and
then the samples were incubated in a 37°C water bath for
30 minutes. Cells were analysed using flow cytometry.
The expression of selected surface markers on PMN was
analysed using flow cytometry. Briefly, peripheral blood
was lysed using 0.84% ammonium chloride. The remaining
leukocytes were stained for surface expression of CD14 (to
exclude monocytes), CD10, CD11b, CD16, CD62L, and
C5aR (CD88) (BD Bioscience San Jose, CA, USA). For flow
cytometry analysis a FACSCanto II and the DIVA software
(Becton Dickinson, BD, New York, NY, USA) were used.
Cell separation and phagocytosis of antibody-coated
necrotic cell material by PMN
PMN and peripheral blood mononuclear cells were iso-
lated from heparinised blood of SLE patients by density
gradient centrifugation on Polymorphprep™ (Axis-ShieldPoc AS, Norway). To obtain necrotic cell material, mono-
nuclear cells were incubated for 10 minutes at 70°C and
stained with propidium iodide (BD Bioscience). The propi-
dium iodide-labelled necrotic cell material (4.5 × 105 cells)
was then incubated with or without an anti-nucleosome
antibody (clone PL2-3; gift from Marc Monestier, Temple
University, Philadelphia, USA) at room temperature for
20 minutes. Normal human serum was used as the nega-
tive control. The autologous PMN were stained with anti-
CD45-FITC (BD Bioscience), and then added to the nec-
rotic cell material, at a concentration of 1.0 × 106 cells/mL
in a total volume of 300 μL, followed by incubation at
37°C for 15 minutes. Cells were washed with phosphate-
buffered saline pH 7.2 containing 0.1% human serum
albumin (Sigma-Aldrich, St. Louis, MO, USA) before ana-
lysis by flow cytometry.
Statistical analysis
Correlations were determined by Spearman’s correlation
test. The Mann-Whitney U-test was used for two-group
comparisons and Kruskal-Wallis test with Dunn’s mul-
tiple comparison test was used for three-group compari-
sons. All P-values were considered significant at P <0.05.
Results
Decreased production of ROS in SLE-PMN
Phagocyte-produced ROS are important effector mole-
cules in the defence against microbes, and could also be
involved in the regulation of the adaptive immune system
[15]. To evaluate PMN function in SLE, we decided to in-
vestigate intracellular ROS production. PMN in peripheral
whole blood from SLE patients (n = 92, Table 1) and
healthy controls (n = 38), were stimulated with either the
protein kinase C activator, PMA, or with opsonised E. coli.
SLE-PMN showed a decreased capacity to produce ROS
ex vivo after activation with both PMA (P <0.0001) and E.
coli (P = 0.0002) (Figure 1). The decreased amount of ROS
produced by SLE-PMN was not associated with the dose
of prednisone or hydroxychloroquine treatment (Figure 2A
and B) or other immune suppressive drugs listed in Table 1
(not shown). Perazzio et al. have previously shown an in-
creased ROS production in SLE-PMN after in vitro activa-
tion with S. aureus or P. aeruginosa using DCFH-DA as
fluorochrome [23]. To evaluate whether this discrepancy
was due to experimental procedure or differences in pa-
tient population, patients (n = 15) and controls (n = 15)
were analysed in parallel with both methods, using S.
aureus, P. aeruginosa, PMA and E. coli as stimuli. Similar
findings where observed between the two methods
(Table 2). SLE-PMN showed a decreased intracellular
ROS formation after PMA activation compared with con-
trols (PhagoBurst test: P = 0.0394 and DCFH-DA: P =
0.0146) whereas no significant difference was observed


































Figure 1 Polymorphonuclear leukocytes (PMN) from patients with
systemic lupus erythematosus (SLE) produced fewer reactive
oxygen species (ROS) than PMN from healthy blood donors. The
capacities of PMN from healthy blood donors (HBD), n = 38, and SLE
patients, n = 92, to produce ROS upon activation with phorbol
12-myristate 13-acetate or opsonised E. coli were investigated using flow
cytometry. The amount of ROS produced is shown as geometric mean
fluorescence intensity (geo mean fluorescence, MFI). The two-sided
Mann-Whitney test was used to calculate the level of significance. The



































































Figure 2 Reactive oxygen species (ROS) production in
polymorphonuclear leukocytes (PMN) from systemic lupus
erythematosus (SLE) patients did not correlate with
Hydroxychloroquine treatment or the dose of prednisone. ROS
production was measured by flow cytometry after ex vivo activation
of PMN with phorbol 12-myristate 13-acetate (A) the amount ROS
produced by SLE-PMN, treated with or without Hydroxychloroquine.
(B) The amount of ROS produced in individual patients plotted
against the dose of prednisone at the day of sampling. The amount
ROS produced is shown as geometric mean fluorescence intensity
(geo mean fluorescence, MFI). The line represents the median value
of each dataset.
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tion was consistent using both methods in contrast to the
findings of Perazzio et al., suggesting differences in patient
populations.
Organ damage was associated with low ROS production
in SLE-PMN
The severity of autoimmune diseases has previously been
associated with decreased ROS production [24–26]. Hence,
to study if the severity of SLE was associated with changes
in ROS production, the patients were divided in two
groups based on the presence of organ damage or not ac-
cording to SLICC/ACR-DI (Table 1). PMN from patients
with SLICC/ACR-DI ≥1 had decreased ROS production,
compared with patients without organ damage (Figure 3A),
when activated with PMA (P = 0.0022). No difference was
seen after activation with E. coli (not shown). Patients with
organ damage were in general older than patients without
(Table 1), however, the age of the patients was not cor-
related with PMA-induced oxidative burst in PMN (not
shown).
Next, we investigated if disease activity, at the time point
of sampling, was associated with ROS production. The
patients were divided into three groups based on the
SLEDAI-2 K [21]: (1) no activity, (2) laboratory parameters
only, such as low complement and anti-double stranded
DNA antibodies; and (3) clinical manifestations, for ex-
ample, nephritis, rash and arthritis. No association betweenROS production and disease activity (P = 0.0654) was ob-
served (Figure 3B).
Phagocytosis of antibody-coated microbes and foreign
material precedes ROS production in PMN. To evaluate
further the function of PMN in SLE, in particular in pa-
tients with organ damage, the phagocytosis capacity was
investigated in 40 out of the 92 patients. Antibody-coated
necrotic cells were chosen as stimuli for phagocytosis to
relate to lupus erythematosus cells, for example, PMN
containing phagocytosed antibody-coated dead cell mate-
rials, a phenomenon almost pathognomonic for SLE. No
Table 2 Comparisons between the PhagoBurst and the DCFH-DA assay
Relative reactive oxygen species formation in SLE patients as% of formation in healthy controls
Stimuli PhagoBurst DCFH-DA P-value
PMA 68 ± 7.7 76 ± 6.2 0.6783
E. coli 84 ± 13 103 ± 13 0.1775
S. aureus 92 ± 8.7 102 ± 6.3 0.2716
P. aeruginosa 88 ± 12 97 ± 14 0.5897
Comparisons of the PhagoBurst assay with the dichlorodihydrofluorescein-diacetate (DCFH-DA) assay according to Perazzio et al. [23]. No significant differences
between the methods were observed. Polymorphonuclear leukocytes (PMN) from systemic lupus erythematosus (SLE) patients (n = 15) and healthy controls
(n = 15) were analysed in parallel with both methods using phorbol 12-myristate 13-acetate (PMA), E. coli, S. aureus or P. aeruginosa as stimuli. ROS formation was
defined as geometric mean fluorescence intensity. Samples from each individual patient were divided by the mean value of the controls to gain the relative ROS
formation in SLE-PMN as% of ROS produced in healthy controls. Values represent mean ± standard error of the mean. The two-sided Mann-Whitney test was used
to calculate the level of significance.
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25; SLICC/ACR-DI ≥1), compared to patients without
organ damage (n = 15; SLICC/ACR-DI = 0), further sug-
gesting that the decreased ROS production in patients
with severe disease is not due to a general unrespon-
siveness (Figure 3C). No associations between disease
activity based on SLEDAI-2 K and the ability to phago-
cytose were observed (not shown).
Low numbers of CD10−CD16low SLE-PMN
During acute inflammation, an increased percentage of
CD10−CD16low neutrophils in peripheral blood are thought
to reflect an increased mobilization of cells from bone
marrow [6,7]. To study the frequency of newly released
CD10−CD16low PMN in peripheral blood, samples from
73 SLE patients, and 27 healthy controls were analysed by
flow cytometry. SLE patients showed lower percentages of
CD10−CD16low PMN (Figure 4), compared with healthy
controls (P <0.0001). Hence, the SLE-PMN were to a high
extent CD10+CD16+ compared with controls (P <0.0001),
which is consistent with a decreased release of PMN from
the bone marrow.
To characterize the activation status of PMN in periph-
eral blood the expression of C5aR, CD11b and CD62L was
investigated. SLE-PMN were to a lesser extent C5aR posi-
tive (P <0.0001), and the positive cells expressed less C5aR
(P <0.0001) (Table 3). No differences in the expression of
CD11b or CD62L were observed (Table 3), indicating that
the cells were only partly activated. C5aR expression and
percentage of CD10−CD16lowPMN were not correlated
with SLICC/ACR-DI or SLEDAI-2 K (not shown).
Discussion
PMN were characterized with respect to function, bone
marrow release and activation to study their role in SLE,
yielding evidence for decreased ROS production in SLE
and autoimmunity. Our data support that SLE-PMN have
decreased capacity to produce ROS ex vivo. The associ-
ation with disease severity, defined as organ damage, fur-
ther strengthened our finding. Low ROS production has
been associated with disease severity of other autoimmuneconditions, including Behcet’s disease [24], Guillain-Barre
syndrome [25] and multiple sclerosis [26], and might be a
common denominator important in the pathogenesis of
autoimmunity.
Interestingly, PMA-induced ROS production was signifi-
cantly reduced in patients with severe disease. However,
neither ROS production after E. coli activation nor phago-
cytosis of necrotic cell material were associated with organ
damage, suggesting that decreased ROS levels after PMA
activation is not a sign of impaired PMN functions in gen-
eral but rather a sign for changed PMN behaviour. While
the activation and control of the NADPH oxidase in neu-
trophils (NOX2) is incompletely understood, it seems that
different agonists encountered by the neutrophils engage
various combinations of kinases and thereby affect the de-
gree of activity of the NADPH complex, and in the end
the amount of ROS produced [27]. To some extent, this
could explain why ROS production after E. coli activation
was not associated with organ damage; E. coli induced a
lower degree of phosphorylation of the NADPH complex
regulating subunits compared with PMA that is known to
push the NADPH complex to its maximal capacity [27].
Hence, PMA revealed altered behaviour in PMN from pa-
tients with organ damage.
While no association between ROS levels and current
disease activity was observed, most patients were in remis-
sion or had low to moderate activity based on SLEDAI-
2 K (Table 1). An association between disease activity and
ROS production could not be excluded based on the avail-
able data. The literature is not concurrent regarding ROS
production by SLE-PMN [23,28,29]. For example, Perazzio
et al. have shown that neutrophils from SLE patients have
an increased capacity to produce ROS, and they did not
find any correlation with organ damage or disease activity
[23]. This discrepancy does not reflect the use of different
methods, as we observed comparable results with both
methods. A more likely explanation is variations in patient
cohorts. We have observed an association between de-
creased ROS formation and disease severity, and a ten-
dency towards increased ROS formation in SLE-PMN in
patients with clinical symptoms. Most patients in our
AB
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Figure 4 Decreased numbers of CD10−CD16low
polymorphonuclear leukocytes (PMN) from patients with
systemic lupus erythematosus (SLE). The frequencies of CD10+CD16+
(mainly segment nucleated neutrophils) and CD10−CD16low (suggested
as a marker for newly released neutrophils) PMN were investigated in
healthy blood donors (HBD, n = 27) and patients (n = 73) using flow
cytometry. The two-sided Mann-Whitney test was used to calculate the
level of significance. The line represents the median value of each
dataset.
Figure 3 Organ damage in systemic lupus erythematosus (SLE)
patients is associated with decreased reactive oxygen species
(ROS) production. ROS production was measured by flow cytometry
after ex vivo activation of peripheral blood polymorphonuclear
leukocytes (PMN) with phorbol 12-myristate 13-acetate. (A) The amount
of ROS produced by PMN from patients with organ damage (Systemic
Lupus International Collaborative Clinics/ACR damage index (SLICC/
ACR-DI) ≥1) was compared with PMN from patients without organ
damage (SLICC/ACR-DI = 0). (B) The amount of ROS produced by PMN
from patients with (1) inactive disease (SLE activity index 2000 (SLEDAI-
2 K) = 0) affected laboratory parameters, such as low complement and
anti-double stranded DNA antibodies, but no clinical symptoms; (2)
laboratory parameters only, and patients with clinical manifestations,
for example, nephritis, rash and arthritis; and (3) clinical symptoms
(P = 0,0654). (C) Phagocytosis of necrotic cell material, in the presence
of serum and anti-nucleosome antibodies, by purified polymorph
nucleated leukocytes (n = 40), was analysed using flow cytometry. The
patients were divided based on organ damage (SLICC/ACR-DI) and
their phagocytosis capacity is shown as% phagocytosing cells. The
two-sided Mann-Whitney test was used to calculate the level of
significance between two groups and Kruskal-Wallis test with Dunn’s
multiple comparison test was used to calculate the level of significance
between three groups. The line represents the median value of each
dataset. MFI, mean fluorescence intensity.
Bengtsson et al. Arthritis Research & Therapy 2014, 16:R120 Page 6 of 8
http://arthritis-research.com/content/16/3/R120
Table 3 Decreased expression of C5aR (CD88) on
polymorphonuclear leukocytes (PMN) from patients with
systemic lupus erythematosus (SLE)
Phenotype Healthy blood donors SLE patients P-value
CD88, % 92 ± 3.8 77 ± 1 ≤0.0001
CD88, geoMFI 466 ± 24 285 ± 4 ≤0.0001
CD62L, % 98 ± 0.3 98 ± 0.2 ns
CD62L, geoMFI 1180 ± 64 1100 ± 42 ns
CD11b, % 100 ± 0 100 ± 0 ns
CD11b, geoMFI 9343 ± 578 8166 ± 270 ns
Comparisons were done between SLE patients and healthy blood donors in
regard of the frequency (%) and amount (geometric mean fluorescence intensity
(geoMFI) of positive cells) of CD88, CD62L and CD11b on CD10+CD16+ PMN.
Values represent mean ± standard error of the mean. The two-sided
Mann-Whitney test was used to calculate the level of significance; ns, not significant.
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more patients with organ damage giving rise to the diver-
gent results. In addition, an influence of genetic factors
could not be excluded.
Corticosteroids have been reported to affect the ROS
production in PMN in a cumulative dose-dependent way
[30], and it is presently unclear whether this effect is due
to increased disease severity. In our study, no correlation
between corticosteroid dose and the amount of intracellu-
lar ROS produced was observed. The patients had rela-
tively low doses of corticosteroids (mean = 5 mg oral
prednisone per day in treated patients) that are likely too
low to affect the function of PMN. This could explain why
no correlation with ROS levels was found. Moreover, other
forms of immune suppressive drugs did neither seem to
affect ROS production in the current setting.
Decreased neutrophil counts occur in SLE [31,32].
While this is partly due to autoantibodies, there is also evi-
dence for direct effects on the bone marrow production of
PMN. Bone marrow from SLE patients has decreased
granulocyte-macrophage colony-forming units [31–33],
and we show here that SLE patients have reduced num-
bers of newly released CD10−CD16low neutrophils [6,7]. In
agreement with earlier observations, these findings suggest
an SLE-associated effect on the bone marrow with de-
creased release of new incompletely differentiated neutro-
phils. Hence, a decreased number of PMN will be found
in the circulation, and with decreased numbers of PMN in
the circulation, a prolonged half-life of the existing cells
likely occur.
Another possibility is that the PMN phenotype in SLE
patients is altered via an as-yet unidentified mechanism.
The CD10 and CD16 molecules are normally stored intra-
cellularly and can be rapidly mobilized to the cell sur-
face upon activation [34]. Hence, an increased percentage
of CD10+CD16+ cells and a corresponding decrease in
CD10−CD16low cells could reflect increased activation of
PMN in vivo in SLE. In addition, the percentage of C5aRwas decreased, indicating that PMN are activated in per-
ipheral blood [35,36]. However, no increase in CD11b
expression and corresponding decrease in CD62L were
observed on SLE-PMN. Taken together, the observed
altered PMN phenotype could be due to prolonged turn-
over of SLE-PMN in the circulation that gives rise to func-
tional changes such as decreased ROS production and an
atypical expression of surface markers.
Conclusions
Our study shows an association between low ROS forma-
tion and disease severity in SLE. This is consistent with
findings in other autoimmune disease, suggesting that a
decrease in NADPH complex-mediated ROS production
is a risk factor in autoimmunity. The phenotype observed
in SLE-PMN could be due to aberrant production of leu-
kocytes in the bone marrow and/or in vivo activation in
the circulation. Future studies will illuminate the role of
ROS formation and PMN in SLE and autoimmunity.
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